Skip to main content

Table 2 Costs and reimbursement for nosocomial VRE and VSE infections

From: Economic burden of nosocomial infections caused by vancomycin-resistant enterococci

  VRE infection (n = 42) VSE infection (n = 42) p-valuea
Costs per patient (EUR) 57,675 (34,253 to 124,079) 38,344 (20,872 to 76,353) 0.030
Costs per patient before the onset of the infection (EUR) 17,893 (10,664 to 32,191) 16,600 (7373 to 24,723) 0.386
Costs per patient after the onset of the infection (EUR) 37,971 (17,786 to 80,662) 23,025 (10,322 to 40,565) 0.049
Reimbursement per patient (EUR) 40,084 (20,128 to 99,501) 26,116 (10,898 to 57,139) 0.032
Loss per patient (EUR) 14,003 (1974 to 32,743) 6883 (3123 to 20,511) 0.227
Median costs attributable to vancomycin-resistance in enterococci infection per patient (EUR)b 13,157(−16,420 to 74,593) 0.036
  1. Values are medians (interquartile range)
  2. aPaired Wilcoxon rank sum test for paired sample
  3. bDifferences between case and control